SOURCE: BioProgress PLC

February 27, 2007 02:01 ET

BioProgress plc announces Technology Launch

Cambridgeshire -- (MARKET WIRE) -- February 27, 2007 --

For Immediate Release                                27 February 2007



                                BioProgress plc

                 Launch of new enabling technology - Meltums(TM)

London, UK, 27 February 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharmaceutical and healthcare company, is pleased to update the market on the launch of a new pharmaceutical enabling technology, Meltums™.

Meltums™ is a new enabling technology using BioProgress's proprietary XGEL™ technology. The technology is a unique lozenge encapsulated with XGEL™ film. With the use of the Company's SoluPol systems, Meltums™ is able to provide a significantly higher drug loading, typically up to several hundred milligrams. The products that can be placed within the Meltums™ system range from vitamins through to potent prescription medicines. BioProgress is currently in discussions with several pharmaceutical companies, as the Meltums™ system addresses their requirement for melt-in-the-mouth delivery of large molecule drugs.

The Meltums™ system is also being targeted to pharmaceutical companies in the area of an alternative single unit dosage form for dysphagic patients. With its unique ability to use its polymer technology, Meltums™ is the first melt-in-the-mouth system that is able to deliver established sustained-release technology.

BioProgress is currently pursuing a number of feasibility studies with pharmaceutical companies and anticipate that launch of the new system will generate revenues over the course of the next 12 months. Products within the nutritional and US OTC sectors are aimed to be launched during 2008.

Steve Martin, Chief Development Officer, BioProgress, said:

"The launch of Meltums™ is an important advance for BioProgress. It has come as a response to our existing relationships with our customers and listening to their requirements. The ability to deliver a new technology and for it to generate revenues early on in its lifecycle is of immense benefit to the Company.

We will be able to formulate our own products for launch as well as work with other companies. With the ability to have a truly ground-breaking technology to deliver sustained-release medicines we believe that this technology could deliver substantial revenues to BioProgress within the next few years."


For further information:


BioProgress Plc                                  + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO

Buchanan Communications                          + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court

About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a vertically integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™ polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.



                      This information is provided by RNS
            The company news service from the London Stock Exchange